{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-004961","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.342854+00:00","generated_at":"2026-05-18T08:53:14.980908+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ZEO ScientifiX launches expansion initiative following Florida's new stem cell law","bullets":["Florida's SB-1768, effective July 1, 2025, authorizes non-FDA-approved stem cell therapies for defined conditions.","ZEO launched a redesigned website (www.zeoscientifix.com) and partnered with Plus4 PR and Small Circle for brand growth.","CEO Ian Bothwell expects additional states to follow, positioning ZEO to lead with its cGMP-compliant biologics platform.","ZEO aims to set the industry standard via ethically sourced biologics, physician education, and compliant product inventory."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-004961","json":"https://secwatch.observer/filing/0001829126-25-004961.json","markdown":"https://secwatch.observer/filing/0001829126-25-004961.md","text":"https://secwatch.observer/filing/0001829126-25-004961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625004961/0001829126-25-004961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625004961/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:53:14.980908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}